Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.

Yin Z. et al, (2023), Cell Rep, 42

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].

Liu X. et al, (2023), J Infect

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Shaw RH. et al, (2023), J Infect

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.

Dijokaite-Guraliuc A. et al, (2023), Cell reports, 42

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.

Moore SC. et al, (2023), Med (N Y)

Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region

Emmenegger M. et al, (2023), iScience, 26, 105928 - 105928

Guillain-Barré Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies.

Davies AJ. et al, (2023), Neurology(R) neuroimmunology & neuroinflammation, 10

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75.

Huo J. et al, (2022), Cell reports

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.

Dijokaite-Guraliuc A. et al, (2022), Cell discovery, 8

CryoEM structures of the multimeric secreted NS1, a major factor for dengue hemorrhagic fever.

Shu B. et al, (2022), Nature communications, 13

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum.

Huo J. et al, (2022), Cell discovery, 8

Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom

Vihta1 KD. et al, (2022), Clinical Infectious Diseases

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.

Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.

Shaw RH. et al, (2022), The Lancet. Respiratory medicine

Evolution of long-term vaccine induced and hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study

Moore SC. et al, (2022)

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

Liu X. et al, (2022), The Journal of infection, 84, 795 - 813

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.

Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18

Accelerating Inhibitor Discovery for Multiple SARS-CoV-2 Targets with a Single, Sequence-Guided Deep Generative Framework

Chenthamarakshan V. et al, (2022)

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.

McNaughton AL. et al, (2022), JCI insight

Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Tuekprakhon A. et al, (2022)

Load More

1
2
3
4
5

Include forthcoming?